Drugs that contain Vibegron

1. List of Gemtesa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8653260 UROVANT Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Apr, 2029

(6 years from now)

US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2025

NCE-1 date: December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic